Return to Results

A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics

new search

Trial Conditions
  • Psoriasis
  • Arthritis, Psoriatic
What is the purpose of this trial?

The purpose of this study is to further evaluate the safety of infliximab and ustekinumab in patients with plaque psoriasis, and other overlapping forms of psoriasis (such as plaque psoriasis and psoriatic arthritis occurring together). The registry study will track the behavior of the disease in response to other therapies, such as other biologic drugs. The registry will also evaluate clinical outcomes, quality of life, and potential risks for patients who may receive standard therapies for psoriasis.

Date & Status

Recruiting

Who can Participate?

Eligibility

Ages:
18 and older

Gender:
Both

Eligibility

Inclusion Criteria:

- Have a diagnosis of psoriasis

- Are candidates for, or are currently receiving conventional systemic agents (eg,
methotrexate, acitretin, cyclosporine or systemic psoralen drug in combination with
Ultraviolet A light [PUVA]) or biologic therapy for psoriasis including those with
chronic severe (extensive and/or disabling) plaque psoriasis who may be treated with
infliximab

- Ability to understand and sign an informed consent form

- Are willing to participate in regular follow-up visits

Exclusion Criteria:

- Refuse to consent or are unwilling to respond to request for a long term information
within the required time frame

- Are participating or have already planned to participate in a clinical trial with
non-marketed investigational agents or are participating in a Centocor-sponsored
clinical trial with marketed agents

Gender: Both
Steward Physician(s)
  • Centocor Ortho Biotech Services, L.L.C. Clinical Trial
Trial Interventions
Biological
  • ustekinumab
  • Biological therapies other than infliximab and ustekinumab
  • infliximab
Drug
  • conventional systemic agents
Physician Researcher

Investigator Name:

  • Centocor Ortho Biotech Services, L.L.C. Clinical Trial

Other Information

Sponsor: Centocor Ortho Biotech Services, L.L.C.
Phase: Phase 4
Trial ID: NCT00508547
Volunteers:  Not Accepting Healthy Volunteers

new search

Connect with Steward

Visit Our Twitter Feed Visit Our Facebook Page Email This Page Print This Page

Subscribe to our patient e-newsletter

Copyright © 2014 Steward Health Care
Connect Healthcare Panacea CMS Solutions